HOME > BUSINESS
BUSINESS
- Taiho, Astex in KRAS Licensing Deal with US Merck
January 7, 2020
- Kyowa Kirin’s Parkinson’s Med Accepted for Review in Europe
January 7, 2020
- Eisai’s Fycompa Now Available in China
January 7, 2020
- Ono, Seikagaku File Novel Osteoarthritis Treatment in Japan
January 7, 2020
- Sumitomo Dainippon Closes US$3 Billion Roivant Deal
January 7, 2020
- Urovant, Now under Sumitomo Dainippon, Seeks US Approval for Vibegron
January 7, 2020
- Eisai Discontinues Development of Epilepsy Drug after Death in PI; “Will Never Be Administered to Humans in the Future”
January 6, 2020
- Astellas Snaps Up US Biotech Xyphos for I/O Technology Platform
January 6, 2020
- Maruho Becomes Solasia’s 2nd Largest Shareholder
January 6, 2020
- Chugai’s Companion Diagnostic OK’ed for Rozlytrek’s ROS1 Use
December 27, 2019
- I/O Biotech BrightPath, Osaka Univ. Link Up for R&D of Immunostimulants
December 27, 2019
- Xofluza Most Detailed Drug for GPs in November: Impact Track
December 26, 2019
- IBL Inks Tick-Borne Disease Deal with South Korea Firm
December 26, 2019
- Nippon BI Chair Thorsten Poehl to Double as President after Merger; Yoshiaki Aono to Head Pharma Biz
December 26, 2019
- Fujifilm PII Alzheimer’s Study Gets Underway in Europe
December 26, 2019
- Opdivo/Yervoy Combo Filed for Frontline NSCLC in Japan
December 26, 2019
- Kyowa Hakko Bio Hit with 18-Day Biz Suspension over GMP Failings
December 25, 2019
- 15% Share Eyed for Jointly Developed Symbicort Generics, Toa Set to Push Uptake with Support App
December 25, 2019
- Gilead Japan Hooks Up with Arthritis-Savvy Eisai for JAK Inhibitor
December 25, 2019
- ASKA Files Uterine Fibroid Drug in Japan
December 25, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
